Blurbs

Analysts Offer Insights on Healthcare Companies: Icon (ICLR), United Therapeutics (UTHR) and Legend Biotech (LEGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Icon (ICLRResearch Report), United Therapeutics (UTHRResearch Report) and Legend Biotech (LEGNResearch Report) with bullish sentiments.

Icon (ICLR)

Jefferies analyst David Windley maintained a Buy rating on Icon today and set a price target of $291.00. The company’s shares closed last Friday at $239.50.

According to TipRanks.com, Windley is a top 100 analyst with an average return of 16.4% and a 70.9% success rate. Windley covers the Healthcare sector, focusing on stocks such as Stevanato Group, IQVIA Holdings, and Sotera Health.

Icon has an analyst consensus of Moderate Buy, with a price target consensus of $288.44, a 23.2% upside from current levels. In a report issued on March 7, Mizuho Securities also maintained a Buy rating on the stock with a $272.00 price target.

See today’s best-performing stocks on TipRanks >>

United Therapeutics (UTHR)

Jefferies analyst Eun Yang maintained a Buy rating on United Therapeutics yesterday and set a price target of $223.00. The company’s shares closed last Friday at $181.20.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 4.9% and a 49.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Taysha Gene Therapies, Blueprint Medicines, and Keros Therapeutics.

United Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $235.83.

Legend Biotech (LEGN)

Jefferies analyst Kelly Shi maintained a Buy rating on Legend Biotech yesterday and set a price target of $73.00. The company’s shares closed last Friday at $38.53.

According to TipRanks.com, Shi ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -30.4% and a 15.6% success rate. Shi covers the Healthcare sector, focusing on stocks such as Bicycle Therapeutics, Heron Therapeutics, and C4 Therapeutics.

Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $65.60, implying a 68.0% upside from current levels. In a report issued on March 15, Barclays also initiated coverage with a Buy rating on the stock with a $53.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ICLR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos